Christopher J. Molloy, PhD, RPh
Interim Provost for
Biomedical and Health Sciences and
Professor, Pharmacology and Toxicology
Phone: (848) 932-5663
Fax: (732) 932-8060
PhD, Rutgers University and UMDNJ
BS (Pharmacy), Rutgers University
PhD, Rutgers University and UMDNJ
Post-Doc, National Cancer Institute, NIH
Dr. Molloy is a molecular and cellular pharmacologist with extensive drug discovery research and management experience in the biopharmaceutical industry. His specific research interests include the molecular mechanisms involved in inflammation and carcinogenesis, with an emphasis on the role of growth factors/cytokines and their intracellular signaling pathways in the control of tissue remodeling. Dr. Molloy has led multiple multidisciplinary drug discovery teams that have advanced new chemical entities from conception into human clinical trials in therapeutic areas such as inflammation, oncology, and cardiovascular disease. Prior to joining Rutgers in 2007, Dr. Molloy was Senior Research Fellow and Team Leader (Inflammation and Pulmonary Diseases) at Johnson & Johnson Pharmaceutical Research and Development, LLC. He also held senior research positions at 3-Dimensional Pharmaceuticals, Inc. and Bristol-Myers Squibb Pharmaceutical Research Institute.
Taylor, D. S., Cheng, X., Pawlowski, J.E., Wallace, A.R., Ferrer, P. and Molloy, C.J.: Epiregulin is a potent vascular smooth muscle cell-derived autocrine mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc. Natl. Acad. Sci. USA 96:1633-1638, 1999.
Grasberger, B.L., Schubert, C., Koblish, H.K., Carver, T.E., Franks, C.F., Zhao, S., Lu, T., LaFrance, L.V., Parks, D.J., Milkiewicz, K.L., Calvo, R.R., Lattanze, J., Ramachandren, K., Petrella, E.C., Cummings, M.D., Manthey, C.L., Deckman, I.C., Maguire, D., Spurlino, J.S., Tomczuk, B.E., Bone, R.F., Salemme, F.R., Maroney, A.C., Pantoliano, M., Bylebyl, G., Zhang, M., Yurkow, E.J., Molloy, C.J. and Bone, R.: Discovery and co-crystal structures of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J.Med. Chem. 48:909-912, 2005.
Koblish, H.K., Zhao, S., Franks, C.F., Donatelli, R.R., Tominovish, R.M., LaFrance, L.V., Leonard, K.A., Gushue, J.M., Parks, D.J., Calvo, R.R., Milkiewicz, K.L., Marugan, J.J., Raboisson, P., Cummings, M.D., Grasberger, B.L., Johnson, D.L., Lu, T., Molloy, C.J., and Maroney, A.C.: Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Therap. 5:160-169, 2006.
Liem-Moolenaar, M., Cerneus, D., Molloy, C.J., End, D., Brown, K.H., de Kam, M., Cohen, A.F., van Hensbergen, Y., Burggraaf, J.: Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in man. Clin. Pharmacol. Ther. 84:481-487, 2008.
Manthey, C.L., Johnson, D.L., Illig, C.R., Tuman, R.W., Zhou, Z., Baker, J.F., Chaikin, M.A., Donatelli, R.R., Franks, C.F., Zeng, L., Crysler, C., Chen, Y., Yurkow, E.J., Boczon, L., Meegalla, S.K., Wilson, K.J., Wall, M.J., Chen, J., Ballentine, S.K., Ott, H., Baumann, C., Lawrence, D., Tomczuk, B.E., Molloy, C.J.: JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol. Cancer Ther. 8:3151-61, 2009.
Awards and Honors